# A Study to Assess Efficacy and Safety of KarXT in Acutely Psychotic Hospitalized Adult Patients With Schizophrenia (EMERGENT-3)

> **NCT04738123** · PHASE3 · COMPLETED · sponsor: **Karuna Therapeutics, Inc., a Bristol Myers Squibb company** · enrollment: 256 (actual)

## Conditions studied

- Schizophrenia
- Schizophrenia; Psychosis

## Interventions

- **DRUG:** Xanomeline and Trospium Chloride Capsules
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04738123
- **Lead sponsor:** Karuna Therapeutics, Inc., a Bristol Myers Squibb company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-04-06
- **Primary completion:** 2022-11-29
- **Final completion:** 2022-12-07
- **Target enrollment:** 256 (ACTUAL)
- **Last updated:** 2024-12-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04738123

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04738123, "A Study to Assess Efficacy and Safety of KarXT in Acutely Psychotic Hospitalized Adult Patients With Schizophrenia (EMERGENT-3)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04738123. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*